RESUMO
Objetivo: evaluar, en mujeres con rotura prematura de membranas pretérmino, si un estabilizador del microbioma vaginal disminuye el riesgo de corioamnionitis clínica, aumenta la latencia al parto y reduce la morbimortalidad materna y neonatal. Sujetos y métodos: estudio de cohortes retrospectivo. Entre 2011-2014 se trató con Geliofil® vaginal a mujeres con rotura prematura de membranas entre las 24,0-29,6 semanas que estaban bajo antibioterapia de amplio espectro. Se compararon los resultados maternos y neonatales con un grupo histórico de características similares (2008-2011). Resultados: veinticinco mujeres fueron tratadas con Geliofil® y veinticuatro pertenecieron al grupo no tratado. El porcentaje de corioamnionitis clínica (32% vs. 33,3%), la edad gestacional al parto (media (desviación estándar)-30,3 (3,4) vs. 30,3 (3,1) semanas) y la latencia al parto (4,4 (5,1) vs. 4,3 (4,1) semanas) fueron similares en ambos grupos. No hubo diferencias en la morbimortalidad materna ni neonatal. Conclusión: el uso de Geliofil® no mejoró los resultados maternos ni neonatales en mujeres con rotura prematura de membranas Pretérmino (AU)
Objective: To evaluate if a vaginal ecosystem stabilizer, Geliofil®, administered to women with preterm prelabour rupture of membranes decreases the occurrence of clinical chorioamnionitis, increases latency to delivery and decreases maternal and neonatal morbimortality. Subjects and methods: Retrospective cohort study. From 2011-2014, vaginal Geliofil® was added to broad-spectrum antibiotic therapy of singleton pregnancies with diagnosis of preterm prelabour rupture of membranes between 24.0 and 29.6 weeks. Maternal and neonatal outcomes were compared with a historical group with similar characteristics (2008-2011). Results: Twenty-five women were treated with Geliofil® and 24 were included in the historic group. No differences were observed between groups in relation to gestational age at delivery (mean (standard deviation)-30.3 (3.4) vs. 30.3 (3.1) weeks), latency to delivery (4.4 (5.1) vs. 4.3 (4.1) weeks) or the occurrence of clinical chorioamnionitis (32% vs. 33.3%), respectively. Moreover, no differences were found in other maternal or neonatal outcomes evaluated. Conclusion: Geliofil®, as a vaginal ecosystem stabilizer, does not improve maternal or neonatal morbimortality in women with preterm prelabour rupture of membranes (AU)
